LON:NCYT Novacyt (NCYT) Share Price, News & Analysis GBX 45.10 -0.40 (-0.88%) As of 05:54 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About Novacyt Stock (LON:NCYT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novacyt alerts:Sign Up Key Stats Today's Range 45.10▼ 4750-Day Range 33▼ 47.7052-Week Range 26.60▼ 86Volume1,219 shsAverage Volume194,457 shsMarket Capitalization£32.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com Read More Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCYT Stock News HeadlinesNOVACYT S.A. EUR1/15TH (CDI) (NCYT.L) H2 FY2025 earnings call transcriptAugust 10, 2026 | finance.yahoo.comNovacyt Delivers Strong First-Half Revenue Growth as Instrument and Clinical Sales AccelerateJuly 28, 2026 | uk.finance.yahoo.comBuy THIS potential Musk supplier before WednesdayA little-known company trading under $1 could become Elon Musk's next supplier, with a possible announcement expected by Wednesday, August 26. Tech investing veteran Jeff Brown notes that the last time Musk struck a deal with a small company in this sector, the stock soared nearly five times in a single session. He has reopened his strategy session with full details on this potential opportunity.August 24 at 1:00 AM | Brownstone Research (Ad)AIM Market Roundup: Thalia Therapeutics, Novacyt, TMT InvestmentsJune 25, 2026 | uk.finance.yahoo.comNovacyt Publishes 2025 Annual Report Amid Ongoing Global ExpansionJune 11, 2026 | tipranks.comNovacyt Sets June AGM, Pushes Advance Voting to Secure QuorumJune 10, 2026 | tipranks.comNovacyt Plans Major Headcount Cut to Slash Cash Burn After Expansion DriveJune 1, 2026 | tipranks.comNovacyt sets June date for in-person AGM and online investor presentationMay 22, 2026 | tipranks.comSee More Headlines NCYT Stock Analysis - Frequently Asked Questions How have NCYT shares performed this year? Novacyt's stock was trading at GBX 35.90 at the beginning of the year. Since then, NCYT shares have increased by 25.9% and is now trading at GBX 45.20. How were Novacyt's earnings last quarter? Novacyt S.A. (LON:NCYT) posted its quarterly earnings results on Thursday, April, 30th. The company reported ($33.00) earnings per share for the quarter. The company earned $20.03 million during the quarter. Novacyt had a negative trailing twelve-month return on equity of 96.44% and a negative net margin of 103.08%. How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), boohoo group (BOO). Company Calendar Last Earnings4/30/2026Today8/23/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolLON:NCYT CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£36.80 million Net Margins-103.08% Pretax MarginN/A Return on Equity-96.44% Return on Assets-27.98% Debt Debt-to-Equity Ratio44.73 Current Ratio4.74 Quick Ratio4.46 Sales & Book Value Annual Sales£20.03 million Price / Sales1.63 Cash FlowGBX 77.71 per share Price / Cash Flow0.58 Book ValueGBX 99.62 per share Price / Book0.45Miscellaneous Outstanding Shares72,502,000Free FloatN/AMarket Cap£32.70 million OptionableNot Optionable Beta1.11 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:NCYT) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.